Document Detail

[Systemic therapy of metastasizing renal cell carcinoma].
MedLine Citation:
PMID:  18825295     Owner:  NLM     Status:  MEDLINE    
Once surgical options have been exhausted, systemic therapy is indicated for metastasizing renal cell carcinoma. Until recently this was carried out using mainly immunotherapeutic concepts with unsatisfactory results. Since the majority of clear cell renal cell carcinomas are well vascularised, angiogenetic inhibition offered an alternative therapy goal. To date, four substances have been approved to control angiogenesis in the therapy of renal cell carcinoma: sunitinib, sorafenib, temsirolimus, as well as a combination of bevacizumab and interferon alpha. Other substances, such as everolimus, pazopanib and axitinib, are currently the subject of clinical trials. Initial data on tolerance and efficacy was presented at this years annual conference of the American Society of Clinical Oncology (ASCO). This article examines current therapy options and ASCO data and discusses future trends.
M Staehler; N Haseke; K Zilinberg; T Stadler; A Karl; C G Stief
Publication Detail:
Type:  English Abstract; Journal Article    
Journal Detail:
Title:  Der Urologe. Ausg. A     Volume:  47     ISSN:  0340-2592     ISO Abbreviation:  Urologe A     Publication Date:  2008 Oct 
Date Detail:
Created Date:  2008-09-30     Completed Date:  2009-01-23     Revised Date:  2013-05-27    
Medline Journal Info:
Nlm Unique ID:  1304110     Medline TA:  Urologe A     Country:  Germany    
Other Details:
Languages:  ger     Pagination:  1357-67     Citation Subset:  IM    
Urologische Klinik und Poliklinik, Ludwig-Maximilians-Universität, Klinikum Grosshadern, Marchioninistrasse 15, 81377 München, Deutschland.
Vernacular Title:
Systemische Therapie des metastasierten Nierenzellkarzinoms.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Angiogenesis Inhibitors / therapeutic use*
Antibodies, Monoclonal / therapeutic use
Antibodies, Monoclonal, Humanized
Benzenesulfonates / therapeutic use
Carcinoma, Renal Cell / blood supply,  drug therapy*,  pathology,  radiography
Chemotherapy, Adjuvant
Clinical Trials as Topic
Disease Progression
Drug Therapy, Combination
Indoles / therapeutic use
Interferon-alpha / therapeutic use
Kidney Neoplasms / blood supply,  drug therapy*,  pathology,  radiography
Pyridines / therapeutic use
Pyrroles / therapeutic use
Sirolimus / analogs & derivatives,  therapeutic use
Tomography, X-Ray Computed
Reg. No./Substance:
0/Angiogenesis Inhibitors; 0/Antibodies, Monoclonal; 0/Antibodies, Monoclonal, Humanized; 0/Benzenesulfonates; 0/Indoles; 0/Interferon-alpha; 0/Pyridines; 0/Pyrroles; 0/sorafenib; 0/sunitinib; 0/temsirolimus; 2S9ZZM9Q9V/bevacizumab; 53123-88-9/Sirolimus

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Anhydrous proton-conducting properties of triazole-phosphonic acid copolymers: a combined study with...
Next Document:  Organochlorine pesticide and polychlorinated biphenyl in calves from north-west Spain.